Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective We aimed to investigate the long-term effects of atomoxetine on growth in Korean children and adolescents with attentiondeficit/ hyperactivity disorder (ADHD). Methods The medical records of 82 subjects (mean age, 9.0±2.0 years; 64 boys) with ADHD treated with atomoxetine for at least 1 year at the Department of Psychiatry at Asan Medical Center were retrospectively reviewed. Height and weight data were prospectively obtained and retrospectively gathered and converted to age- and gender-corrected z scores using norms from Korean youths. Growth changes were analyzed using random coefficients models with changes in height or weight z scores as the dependent variables. Results Height z scores significantly decreased during the treatment period (β=-0.054, p=0.024). Height z scores decreased during the 1st year of treatment (β=-0.086, p=0.003), but did not change after the 1st year. Weight z scores did not change significantly during treatment (β=0.004, p=0.925). Conclusion Our results suggest that long-term atomoxetine treatment may be associated with deficits in height growth in Korean youths, although this effect was minor and tended to be attenuated over the first year. Because of the limitations of this study such as retrospective design and selection bias, further prospective studies are needed.
Abstract
Objective We aimed to investigate the long-term effects of atomoxetine on growth in Korean children and adolescents with attentiondeficit/ hyperactivity disorder (ADHD). Methods The medical records of 82 subjects (mean age, 9.0±2.0 years; 64 boys) with ADHD treated with atomoxetine for at least 1 year at the Department of Psychiatry at Asan Medical Center were retrospectively reviewed. Height and weight data were prospectively obtained and retrospectively gathered and converted to age- and gender-corrected z scores using norms from Korean youths. Growth changes were analyzed using random coefficients models with changes in height or weight z scores as the dependent variables. Results Height z scores significantly decreased during the treatment period (β=-0.054, p=0.024). Height z scores decreased during the 1st year of treatment (β=-0.086, p=0.003), but did not change after the 1st year. Weight z scores did not change significantly during treatment (β=0.004, p=0.925). Conclusion Our results suggest that long-term atomoxetine treatment may be associated with deficits in height growth in Korean youths, although this effect was minor and tended to be attenuated over the first year. Because of the limitations of this study such as retrospective design and selection bias, further prospective studies are needed.
참고문헌 (15)
- Hammerness P, "Atomoxetine for the treatment of attention-deficit", hyperactivity disorder in children and adolescents: a review, 2009, pp.5, 215~226
- Spencer TJ, "Effects of atomoxetine on growth in children with attentiondeficit", hyperactivity disorder following up to five years of treatment, 2007, pp.17, 689~699
- Spencer TJ, "Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit", hyperactivity disorder, 2005, pp.116, e74~e80
- Kratochvil CJ, "Effects of long-term atomoxetine treatment for young children with attention-deficit", hyperactivity disorder, 2006, pp.45, 919~927
- Donnelly C, "Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD", J Am Acad Child Adolesc Psychiatry, 48, pp.176~185 (2009)[DOI]
- Wilens TE, "Long-term atomoxetine treatment in adolescents with attention-deficit", hyperactivity disorder, 2006, pp.149, 112~119
- Michelson D, "CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD", J Am Acad Child Adolesc Psychiatry, 46, pp.242~251 (2007)[DOI]
- Kitada M, "Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6", Int J Clin Pharmacol Res, 23, pp.31~35 (2002)
- Liang B, "Effect of 24 Cytochrome P450 2D6 variants found in the Chinese population on atomoxetine metabolism in vitro", Pharmacology, 97, pp.78~83 (2016)
- Korea Center for Disease Control and Prevention, "2007 Korean Children and Adolescents Growth Standard" (2008), Korean Pediatric Society
- Reed VA, "The safety of atomoxetine for the treatment of children and adolescents with attention-deficit", hyperactivity disorder: a comprehensive review of over a decade of research, 2016, pp.30, 603~628
- Vitiello B, "Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function", Child Adolesc Psychiatr Clin N Am, 17, pp.459~474 (2008)[DOI]
- Wilens T, "Do children and adolescents with ADHD respond differently to atomoxetine?", J Am Acad Child Adolesc Psychiatry, 45, pp.149~157 (2006)[DOI]
- Troost PW, "Atomoxetine for Attention-Deficit", Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot Study, 2006, pp.16, 611~619
- Valicenti-McDermott M, "Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease", J Dev Behav Pediatr, 27(2 Suppl), pp.S128~S136 (2006)[DOI]